Lpin1 in human visceral and subcutaneous adipose tissue: similar levels but different associations with lipogenic and lipolytic genes.
LPIN1 is a gene with important effects on lipidic and metabolic homeostasis. Human subcutaneous LPIN1 expression levels in adipose tissue are related with a better metabolic profile, including insulin sensitivity markers. However, there are few data on the regulation of LPIN1 in visceral adipose tissue (VAT). Our aim was to perform a cross-sectional analysis of VAT compared with subcutaneous (SAT) LPIN1 expression in a well-characterized obese cohort, its relation with the expression of genes involved in lipid metabolism, and the in vitro response to lipogenic and lipolytic stimuli. A downregulation of total LPIN1 mRNA expression in subjects with obesity was found in VAT similarly to that in SAT. Despite similar total LPIN1 mRNA levels in SAT and VAT, a close relationship with clinical parameters and with many lipogenic and lipolytic genes was observed primarily in SAT depot. As shown in the in vitro analysis, the low-grade proinflammatory environment and the insulin resistance associated with obesity may contribute to downregulate LPIN1 in adipose tissue, leading to a worse metabolic profile.
Endocrinology and Diabetes Unit, Hospital Universitari Joan XXIII, C/Dr. Mallafré Guasch 4, Tarragona, Spain. mmiranda.hj23.ics@gencat.cat
Merce
M
Miranda
Xavier
X
Escoté
María J
MJ
Alcaide
Esther
E
Solano
Victòria
V
Ceperuelo-Mallafré
Pilar
P
Hernández
Martin
M
Wabitsch
Joan
J
Vendrell
D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism; D000273:Adipose Tissue / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000328:Adult; D000368:Aged; D015153:Blotting, Western; D015992:Body Mass Index; D002454:Cell Differentiation; D002478:Cells, Cultured; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D018076:DNA, Complementary / Q000096:biosynthesis / Q000235:genetics; D005260:Female; D015870:Gene Expression / Q000235:genetics; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology; D050356:Lipid Metabolism / Q000187:drug effects / Q000235:genetics*; D008066:Lipolysis / Q000187:drug effects / Q000235:genetics*; D008297:Male; D024821:Metabolic Syndrome / Q000378:metabolism; D008875:Middle Aged; D009687:Nuclear Proteins / Q000096:biosynthesis* / Q000235:genetics; D010711:Phosphatidate Phosphatase; D050151:Subcutaneous Fat / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D000318:Adrenergic beta-Agonists; D018076:DNA, Complementary; D007004:Hypoglycemic Agents; D007328:Insulin; D009687:Nuclear Proteins; D014409:Tumor Necrosis Factor-alpha; C485999:LPIN1 protein, human; D010711:Phosphatidate Phosphatase; D007545:Isoproterenol